Hyalron Pre-filled Injection (Sodium Hyaluronate)

Adult administration

As sodium hyaluronate, administer 25 mg once a week for 5 consecutive weeks into the intra-articular space of the knee or shoulder (shoulder joint space, subacromial bursa, or bicipital tendon sheath), but adjust the frequency of administration appropriately according to symptoms. This medication should be administered under strict sterile conditions into the intra-articular space.

This medication should not be used in certain patients. Patients who have had allergic reactions to this medication or its ingredients, those with skin diseases or infections in the joint area, patients with liver dysfunction or a history of liver disease, and those allergic to avian proteins should not receive this medication. While using this medication, patients should be closely monitored as serious allergic reactions, such as shock, may occur. If swelling around the face or eyes, rashes, hives, or itching occur, administration should be immediately stopped, and appropriate treatment should be received. Temporary pain, swelling, redness, heat sensation, severe pressure, or bruising may occur at the injection site, and rarely, symptoms such as fluid accumulation may appear. Nausea, vomiting, fever, and headache may also occur. In cases of severe arthritis, this medication may exacerbate inflammation, so it is advisable to administer it after the inflammation subsides. After administration, the joint area should be stabilized, and care should be taken to prevent the medication from leaking out of the joint. When administered to patients with rheumatoid arthritis or gouty arthritis, temporary exacerbation of inflammation may occur, so caution is needed. It is preferable to avoid vigorous exercise or prolonged weight-bearing activities within 48 hours after administration. The safety and efficacy of this medication when used in conjunction with other intra-articular administration drugs have not been established; therefore, co-administration should be avoided. Women who are pregnant or may become pregnant should use this medication cautiously, as its safety has not been established, and only when the benefits of treatment outweigh the risks. Additionally, this medication can be passed through breast milk, so breastfeeding should be avoided during treatment. The safety in children has not been sufficiently established; therefore, it should only be administered cautiously when necessary. Elderly patients may have diminished physical function, so special attention should be given during administration. This medication must be injected into the joint under sterile conditions, and if symptoms do not improve, administration should be stopped after 5 applications. If there is excess joint fluid, it should be aspirated beforehand. Intravenous injection is prohibited, and it is not used for ophthalmic purposes. During injection, due to high viscosity, a syringe with an appropriate size needle should be used, and the ampoule should be shaken to ensure the injection solution collects well before slowly aspirating into the syringe. When cutting the ampoule, it is safe to do so after disinfecting to prevent foreign matter from entering. Furthermore, caution should be taken as precipitation may occur when mixed with certain disinfectants. This medication is for single use, and any remaining after opening should be discarded quickly. It is advisable to administer this medication after first injecting a local anesthetic.

Serious side effects

Shock, hives.

Mild side effects

Swelling (facial, eyelid, etc.), facial flushing, rarely rashes, itching, pain (mainly transient pain after administration), swelling, redness, heat sensation, severe localized pressure, petechiae, nausea, vomiting, fever, headache.

This medication should be stored in a tightly sealed container that blocks light, maintaining a storage temperature between 1 and 30 degrees Celsius to safely preserve its effectiveness.

Appearance

A colorless, transparent viscous liquid contained in a glass vial sealed with rubber stoppers at both ends (part of the prefilled syringe system).

Package unit

2.5 mL/vial × 5 vials, 10 vials